%0 Journal Article
%T Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy?
%A Jiajin Yang
%A Kuan Hu
%A Yufan Zhou
%A Yun Huang
%A Zeyu Zhang
%A Zhiming Wang
%J Archive of "OncoTargets and therapy".
%D 2019
%R 10.2147/OTT.S187357
%X Microvascular invasion (MVI) has been proved to be an independent risk factor for the recurrence of HCC. If promptly treated, the recurrence rate can be reduced and the total survival time can be prolonged. The aim of this study is to analyze the effect of sorafenib on the clinical outcomes in HCC patients with MVI after curative hepatectomy
%K sorafenib
%K hepatocellular carcinoma
%K microvascular invasion
%K hepatectomy
%K survival rate
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334782/